Phase 4 Dupilumab Findings on Atopic Dermatitis in Skin of Color, With Orit Markowitz, MD

The 2025 European Academy of Dermatology and Venereology (EADV) Congress in Paris featured new phase 4 data on the impact of dupilumab treatment on patients with skin of color who live with moderate to severe atopic dermatitis.1

In a recent interview with HCPLive, Orit Markowitz, MD, an assistant professor of dermatology at the Icahn School of Medicine at Mount Sinai, highlighted these data as well as a subanalysis of the findings looking at line-field optical coherence tomography.2 Markowitz and her fellow investigators noted that patients with skin of color commonly experience increased disease severity, prevalence, and quality-of-life burdens and are also historically underrepresented in clinical research.

“I think that there are certain skin types and ethnicities that tend to be underrepresented in studies compared to the incidence of disease at large,” Markowitz explained. “Clearly, inflammatory issues such as atopic dermatitis have a very diverse patient population when we look at incidents in the United States and throughout the world. And when you look at the percentage of these patients in the clinical trials, it's limited, so getting very clear data on what we saw demonstrates that it's very similar in diverse skin types, as it is, in terms of the medication’s efficacy and side effect profile, which is very good.”

In their study, Markowitz et al noted that subgroup analyses of dupilumab phase 3 data, despite limited sample sizes, demonstrated a risk-benefit profile in patients with skin of color similar to that of the overall population of patients with atopic dermatitis. Therefore, the phase 4, open-label, single-arm, 24-week DISCOVER study was conducted to further assess the efficacy and safety of dupilumab in such patients.1,2

“It's almost become a gold standard in terms of managing moderate to severe atopic dermatitis we've seen in various publications, the benefits early on and in adulthood in this medication,” Markowitz said. “It was very helpful to see that we found very similar overlap in the skin of color patient population, and that was the poster presented at EADV in my site.”

Markowitz noted an additional poser she had presented at EADV assessing atopic dermatitis lesional, perilesional, and post-inflammatory pigmentary skin structural changes in patients with moderate-to-severe disease and skin of color. They examined subjects following dupilumab treatment via non-invasive line-field confocal optical coherence tomography (LC-OCT).2

“First and foremost, imaging is colorblind, so it's a wonderful way to kind of get data on all patients, and especially diverse patients, where there may be some challenges in terms of diagnosis and management,” Markowitz said. “What was very unique in this study was looking at post-inflammatory, hyper, and hypopigmentation. In the study at large, we don't often do that, and it is so critical in terms of managing patients, especially diverse patients.”

The quotes used in this interview summary were edited for the purposes of clarity.

Markowitz’s disclosures include the following: Acelyrin, Alastin, Alumis, Amgen, Argenix, Bristol Myers, Candela Medical, Celldex, DAMAE Medical, Dermtech, Eli Lilly, Evommune, Galderma, Incyte, Inmagene, Janssen, Pfizer, RAPT, Regeneron Pharmaceuticals Inc., Sanofi, SquibbCelldex – principal investigator.

References

1. Alexis A, Markowitz O, Shumel B, et al. Dupilumab Monotherapy in Patients With Skin of Color and Moderate-to-Severe Atopic Dermatitis: Results From a Phase 4, Open-Label Study. Presented at the European Academy of Dermatology and Venereology (EADV) 2025 Congress. Paris, France. September 17-20, 2025.

2. Markowitz O, Shiao N, Shumel B, et al. Dupilumab Monotherapy Improves Multiple Skin Measures in Skin of Color Patients With Atopic Dermatitis as Measured by Line-Field Optical Coherence Tomography. Presented at the European Academy of Dermatology and Venereology (EADV) 2025 Congress. Paris, France. September 17-20, 2025.